Navigation Links
Salt Lake City Medical Research Center Tests New Drug To Treat Painful Menstrual Cramps

SALT LAKE CITY, Jan. 11 /PRNewswire/ -- A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school.

Current therapies for the condition (including NSAIDs and 'off label' oral contraceptives) are not completely effective for all women and sometimes do not provide satisfactory relief of symptoms, particularly in women with more severe pain. The investigational new drug, presently named VA111913, is designed to tackle the cause of the cramps that can leave some women bedridden, rather than just the symptoms.

The Jean Brown Research center is recruiting women of childbearing age who suffer from dysmenorrhea and normally take medicines to treat their menstrual cramps to take part in a clinical research trial. The trial will assess the effect that treatment with VA111913 has on pain experienced during menstruation, including the intensity and duration of the pain.

Menstrual cramps are caused by contractions of the uterus during menstruation. In earlier studies, VA111913 has been shown to control abnormal contraction of smooth muscle, such as that found in the uterus wall. By targeting receptors of a hormone called vasopressin it is hoped the investigational new drug will prove effective in controlling the abnormal contractions that cause period pain.

The study, which involves centers in the US and the UK, is a Phase II trial designed to show whether the drug is effective in treating menstrual cramps. Results from this trial are expected in 2010 and if it, and further studies, are successful, the drug could be available in four years.

Dr. Yamashiro, the physician leading the trial at Jean Brown Research, said, "Dysmenorrhea affects a large number of women and there is currently no targeted therapy to treat the condition. Earlier results with this investigational new drug showed effects on the contraction of smooth muscle and it is hoped that VA111913 could potentially offer an effective treatment to the many women whose lives are affected by this painful and debilitating condition."

Physicians and patients interested in learning more about this clinical trial can contact Jean Brown Research at 801-261-2000 for more information and to find out if they are initially eligible to screen for the study.

The trial is being sponsored by UK-based company Vantia Therapeutics, which discovered the new drug.

SOURCE Jean Brown Research



SOURCE Jean Brown Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverness Medical Innovations to Present at the J.P. Morgan Healthcare Conference on January 12, 2010
2. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
3. ViVre Medical Announces $6,000,000 Gift
4. University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System
5. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
6. FDA Advisory Panel Votes 15 to 0 in Favor of Approving Envoy Medicals Esteem(R) Fully Implantable Hearing Restoration System
7. Nonin Medical Announces Expanded Distribution Partnership With CareFusion
8. Symmetry Medical Announces Restructuring
9. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
10. Cantel Medical Authorizes Semiannual Dividend
11. Connectyx Announces Distribution Partnership with United States Medical Supply
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):